Related Experiment Videos
Inhibition of fibrosis in TSK mice by blocking mast cell degranulation
The Journal of Rheumatology
|April 1, 1987
Abstract:
The Tsk mouse has a genetically transmitted connective tissue disease whose skin lesions resemble those of scleroderma. After treatment with disodium cromoglycate, a marked decrease in skin fibrosis was observed, raising the possibility that disodium cromoglycate may be a potential treatment for human scleroderma.
Insights
Disodium cromoglycate significantly reduced skin fibrosis in Tsk mice, a model for scleroderma. This suggests potential therapeutic benefits for treating human scleroderma.
Area of Science:
- Connective tissue diseases
- Dermatology
- Pharmacology
Background:
- The Tsk mouse model exhibits genetically transmitted connective tissue disease with skin lesions similar to human scleroderma.
- Scleroderma is characterized by significant skin fibrosis, impacting patient quality of life.
Purpose of the Study:
- To investigate the therapeutic potential of disodium cromoglycate in a mouse model of scleroderma.
- To evaluate the effect of disodium cromoglycate on skin fibrosis in Tsk mice.
Main Methods:
- Treatment of Tsk mice with disodium cromoglycate.
- Assessment of skin fibrosis following treatment.
Main Results:
- A marked decrease in skin fibrosis was observed in Tsk mice after disodium cromoglycate treatment.
- Disodium cromoglycate demonstrated anti-fibrotic effects in the Tsk mouse model.
Conclusions:
- Disodium cromoglycate shows promise as a potential treatment for scleroderma.
- Further research is warranted to explore disodium cromoglycate for human scleroderma therapy.